| abstract |
The present invention relates to a triazolopyridazine compound of formula (I), its N oxide, pharmaceutically acceptable salts and solvates, wherein D represents deuterium, using these compounds as protein tyrosine kinase regulators, especially are inhibitors of c-Met, and the compounds are for use in reducing or inhibiting the kinase activity of c-Met in a cell or a subject (subject), and modulating c-Met expression in a cell or subject (subject), and Use of these compounds for the prevention or treatment of cell proliferative disorders and/or c-Met-related disorders in a subject (subject). The invention further relates to pharmaceutical compositions comprising the compounds of the invention and methods of treating conditions such as cancer and other cell proliferative disorders. |